SMART (Single Maintenance and Reliever Therapy) or MART (Maintenance and Reliever Therapy) are a next-generation asthma treatment containing an ICS (inhaled corticosteroid) with formoterol (long-acting beta agonist) combined into one inhaler.

The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta2-agonists as reliever therapy in adolescents and adults with asthma, across the range of asthma severity. This recommendation represents the most fundamental change in asthma management for many decades.

Jun 15, 2020 · Preferred options for adults and adolescents include a low-dose ICS/formoterol as both daily and as-needed treatment or a medium-dose ICS/LABA as daily maintenance treatment with a SABA as...

SMART or MART therapy stands for "Single Maintenance and Reliever Therapy." It uses one inhaler that combines two medicines: an inhaled corticosteroid (ICS) to treat inflammation, and formoterol, a long-acting beta-2 agonist (LABA) to help open up the lungs.

Instead, the current Global Initiative for Asthma (GINA) Report recommends the use of the combination of inhaled corticosteroids (ICS) with the rapid/long-acting beta-2 agonist formoterol, although the use in steps 1 and 2 is still off-label in the EU and in many countries.

For patients 12 years or older with moderate to severe persistent asthma, a single ICS/formoterol inhaler (i.e., SMART), used daily and as needed, is conditionally preferred. 5 GINA recommends ...

The Global Initiative for Asthma recommends that low-dose inhaled corticosteroid (ICS)/formoterol be preferred to short-acting beta2-agonists as reliever therapy in adolescents and adults with asthma, across the range of asthma severity. This recommendation represents the most fundamental change in asthma management for many decades.

Importantly, ICS-formoterol MART reduced the severe exacerbation risk by 23% (RR 0.77 [0.60–0.98]) compared with doubling the maintenance dose of ICS in ICS/LABA maintenance and SABA reliever.

A variety of combination ICS/long-acting beta-2 agonist (LABA) inhalers containing an ICS and the LABA formoterol are licensed for use as anti-inflammatory reliever (AIR) therapy and maintenance and reliever therapy (MART) in the UK, such as Symbicort ®, Fostair ®, DuoResp ®, Fobumix ®, Luforbec ®, and Wockair ®.

The Global Initiative for Asthma strategy recommends that inhaled corticosteroids (ICS)/formoterol is the preferred reliever therapy across the range of asthma severity for adolescents and adults with asthma, and that ICS/short-acting beta2-agonists (SABA) is …